Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate.

Abstract

Imatinib mesylate is a selective protein kinase inhibitor, highly active in patients with chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). Cutaneous toxicity, a well-recognized, dose-related side-effect of imatinib mesylate, has been reported in 18 to 69% of patients with GIST treated with doses ranging from 400 to 800 mg once a day. In this case-report a severe skin reaction observed in a patient with GIST treated with imatinib mesylate, in an adjuvant setting and whose severity led to definitive drug discontinuation, is described. Therapeutic management and clinical course are illustrated.

• Authors: Virginia Ferraresi, Caterina Catricalà, Mariangela Ciccarese, Angela Ferrari, Massimo Zeuli, Francesco Cognetti
• Journal: Anticancer research (Anticancer Res) 2006 Nov-Dec Vol. 26 Issue 6C Pg. 4771-4 ISSN: 0250-7005 [Print] Greece
• PMID: 17214339 (Publication Type: Case Reports, Journal Article)

Chemical References

• Benzamides
• Piperazines
• Pyrimidines
• Imatinib Mesylate

Topics

• Benzamides
• Erythema (chemically induced)
• Female
• Gastrointestinal Stromal Tumors (drug therapy)
• Humans
• Imatinib Mesylate
• Middle Aged
• Piperazines (adverse effects, therapeutic use)
• Pyrimidines (adverse effects, therapeutic use)